Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-28

Last Posted Date: 2021-01-12

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT02917941

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Scopolamine
Drug: TAK-071
Drug: Donepezil
Drug: Scopolamine Placebo
Drug: TAK-071 Placebo
Drug: Donepezil Placebo

First Posted Date: 2016-09-28

Last Posted Date: 2019-06-14

Lead Sponsor: Takeda

Target Recruit Count: 18

Registration Number: NCT02918266

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

Phase 2

Withdrawn

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Vedolizumab intravenous injection
Drug: Vedolizumab subcutaneous injection

First Posted Date: 2016-09-23

Last Posted Date: 2016-09-23

Lead Sponsor: Takeda

Registration Number: NCT02913508

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-935 Tablets
Drug: TAK-935 Oral Solution

First Posted Date: 2016-09-20

Last Posted Date: 2018-09-19

Lead Sponsor: Takeda

Target Recruit Count: 9

Registration Number: NCT02906813

Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain

Completed

Conditions: Breakthrough Cancer Pain

Interventions: Other: No Intervention

First Posted Date: 2016-09-14

Last Posted Date: 2019-11-22

Lead Sponsor: Takeda

Target Recruit Count: 3765

Registration Number: NCT02899884

Locations: 🇪🇸
Hospital Universitario San Juan de Alicante, San Juan, Alicante, Spain
🇪🇸
Hospital General Universitario de Elda-Virgen de La Salud, Elda, Alicante, Spain
🇪🇸
Hospital Universitari Son Espases, Palma de Mallorca, Baleares, Spain

and more 33 locations

TAK-438 Bismuth Drug Interaction Study

Phase 1

Completed

Conditions: Helicobacter Pylori

Interventions: Drug: Clarithromycin
Drug: Amoxicillin
Drug: Tripotassium bismuth dicitrate
Drug: Lansoprazole
Drug: TAK-438

First Posted Date: 2016-09-08

Last Posted Date: 2019-01-03

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT02892409

Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients

Phase 3

Completed

Conditions: Heartburn
Gastroesophageal Reflux Disease

Interventions: Drug: Placebo
Drug: Dexlansoprazole

First Posted Date: 2016-08-19

Last Posted Date: 2019-07-05

Lead Sponsor: Takeda

Target Recruit Count: 217

Registration Number: NCT02873689

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
The People's Hospital of Guangxi Zhuang Autonomous Region, Nan Ning, Guang XI, China

and more 22 locations

Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

Phase 3

Terminated

Conditions: Erosive Esophagitis

Interventions: Drug: Dexlansoprazole
Drug: Placebo
Drug: Lansoprazole

First Posted Date: 2016-08-19

Last Posted Date: 2019-02-22

Lead Sponsor: Takeda

Target Recruit Count: 37

Registration Number: NCT02873702

Locations: 🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Three Gorges Central Hospital, Chong Qing, Chong Qing, China

and more 22 locations

A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease

Completed

Conditions: Inflammatory Bowel Disease

Interventions: Other: No Intervention

First Posted Date: 2016-08-10

Last Posted Date: 2019-08-14

Lead Sponsor: Takeda

Target Recruit Count: 310

Registration Number: NCT02861118

Phase 3 Alogliptin Pediatric Study

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Alogliptin Benzoate
Drug: Placebo

First Posted Date: 2016-08-04

Last Posted Date: 2022-10-19

Lead Sponsor: Takeda

Target Recruit Count: 152

Registration Number: NCT02856113

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 64 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy